Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension
H. Gavras, A. Flessas, T. J. Ryan, H. R. Brunner, D. P. Faxon and I. Gavras
A patient with intractable congestive cardiac failure secondary to
renovascular hypertension and severe coronary artery disease was infused
with the competitive antagonist of angiotensin II, saralasin acetate. The
infusion produced an impressive increase in cardiac output and left
ventricular stroke work index in parallel with a striking decrease in the
systemic and pulmonary vascular resistance, the coronary resistance, and
the myocardial oxygen consumption. It is suggested that angiotensin
inhibition may present advantages over other forms of treatment of
congestive cardiac failure in selected cases.
Novel targets of ANG II regulation in mouse heart identified by serial analysis of gene expression
Schwartz et al.
Am. J. Physiol. Heart Circ. Physiol. 2004;287:H1957-H1966.
ABSTRACT
| FULL TEXT
Angiotensin II contributes to arterial compliance in congestive heart failure
Lage et al.
Am. J. Physiol. Heart Circ. Physiol. 2002;283:H1424-H1429.
ABSTRACT
| FULL TEXT
Angiotensin II Type 1 Receptor Blockers
Burnier
Circulation 2001;103:904-912.
FULL TEXT
Role of Angiotensin and Its Inhibition in Hypertension, Ischemic Heart Disease, and Heart Failure
Gavras and Brunner
Hypertension 2001;37:342-345.
ABSTRACT
| FULL TEXT
Effect of Ramipril on Cardiovascular Events in High-Risk Patients
Weinsaft et al.
NEJM 2000;343:64-66.
FULL TEXT
The Economics of Therapeutic Advances: The Paradigm of Sympathetic Suppression in Chronic Heart Failure
Gavras et al.
Arch Intern Med 1999;159:2634-2636.
FULL TEXT
Combined Sympathetic Suppression and Angiotensin-Converting Enzyme Inhibition in Congestive Heart Failure
Manolis et al.
Hypertension 1997;29:525-530.
ABSTRACT
| FULL TEXT
Suppressing Sympathetic Activation in Congestive Heart Failure : A New Therapeutic Strategy
Manolis et al.
Hypertension 1995;26:719-724.
ABSTRACT
| FULL TEXT
